Where is Genmab A/S (GMAB) Headed According to Wall Street?

Genmab A/S (NASDAQ:GMAB) is one of the best healthcare stocks under $50 to invest in. Genmab A/S (NASDAQ:GMAB) announced on January 21 that the worldwide net trade sales of DARZALEX, including sales of the subcutaneous product (daratumumab and hyaluronidase-fihj, sold under the tradename DARZALEX FASPRO® in the U.S.), as reported by J&J, came up to $14.351 billion in 2025. Net trade sales were $8.266 billion in the U.S. and $6.085 billion in the rest of the world. Management reported that Genmab A/S (NASDAQ:GMAB) receives royalties on the worldwide net sales of DARZALEX under the exclusive worldwide license to J&J for the development, manufacture, and commercialization of daratumumab. This includes both the intravenous and SC products.

In another development, H.C. Wainwright revised the price target on Genmab A/S (NASDAQ:GMAB) to $39 from $41 on January 20, maintaining a Buy rating on the shares. The firm told investors that although EPCORE DLBCL-1 failed its primary endpoint, Epkinly may still gain full approval. BofA also adjusted the price target on Genmab A/S (NASDAQ:GMAB) to $38.50 from $34.70 on January 19, reaffirming a Buy rating. The firm stated that the company previously outlined a “catalyst-rich” fiscal 2026, and BofA is “bullish” on Genmab A/S’s (NASDAQ:GMAB) major catalysts in 2026 as it believes each could offer a $2 billion peak sales opportunity in attractive markets.

Genmab A/S (NASDAQ:GMAB) is an international biotechnology company that develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes DARZALEX to treat certain indications of multiple myeloma, TEPEZZA for the treatment of thyroid eye disease, and Arzerra to treat certain indications of chronic lymphocytic leukemia.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.